Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Resmetirom is the first drug to show both MASH resolution and fibrosis improvement in a late-stage clinical trial.
A personalized approach to diagnosis and treatment is needed when viral hepatitis and fatty liver disease coexist.
Skipping breakfast and late-night eating can worsen MASLD, while intermittent fasting may help.
More people who participated in a specialized program lost weight compared with those who received standard care.
MASLD and MASH can lead to liver fibrosis, cirrhosis and liver cancer.
An increase in fatty liver disease could double liver cancer cases and nearly triple the need for transplants by 2050.
Name change emphasizes the role of metabolic dysfunction in fatty liver disease.
People with type 2 diabetes also had a fivefold higher risk for liver cancer.
NAFLD is associated with risk factors such as obesity and inflammatory biomarkers and with events including heart attacks and strokes.
For people with NAFLD or NASH, treating metabolic problems may offer benefits beyond liver disease.
Advanced fatty liver disease led to a greater need for medical care and more difficulty with daily activities.
In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.
Men, people with obesity and people who smoke are more likely to develop NAFLD.
Lean people had a higher mortality rate despite experiencing fewer metabolic problems.
Restoration of gut function and microbial diversity could lead to improvement of hepatic encephalopathy.
While hepatitis C remains a leading cause, cirrhosis is increasingly caused by fatty liver disease and alcohol use.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.